KalVista Pharmaceuticals
Stock Forecast, Prediction & Price Target
KalVista Pharmaceuticals Financial Estimates
KalVista Pharmaceuticals Revenue Estimates
KalVista Pharmaceuticals EBITDA Estimates
KalVista Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 4/30/2022 | 4/30/2023 | 4/30/2024 | 4/30/2026 | 4/30/2027 | 4/30/2028 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $118.32M Low: $71.84M High: $205.19M avg. 0% | Avg: $165.65M Low: $100.58M High: $287.28M avg. 40.00% | Avg: $230.40M Low: $139.89M High: $399.56M avg. 39.08% | |
Net Income
% change YoY
| $-68.51M N/A | $-74.85M -9.25% | $-126.64M -69.19% | Avg: $-25.81M Low: $-46.57M High: $29.00M avg. 79.61% | Avg: $8.54M Low: $-15.06M High: $33.19M avg. 133.10% | Avg: $42.48M Low: $20.79M High: $83.03M avg. 397.13% | |
EBITDA
% change YoY
| $-94.51M N/A | $-92.10M 2.54% | $-134.28M -45.79% | Avg: $-23.66M Low: $-41.03M High: $-14.36M avg. 82.37% | Avg: $-33.13M Low: $-57.45M High: $-20.11M avg. -40.00% | Avg: $-46.08M Low: $-79.91M High: $-27.97M avg. -39.08% | |
EPS
% change YoY
| -$2.8 N/A | -$2.68 4.28% | -$3.44 -28.35% | Avg: -$0.5 Low: -$1.67 High: $1.04 avg. 85.53% | Avg: $0.18 Low: -$0.54 High: $1.19 avg. 136.18% | Avg: $1.52 Low: $0.75 High: $2.98 avg. 746.29% | |
Operating Expenses
% change YoY
| $96.61M N/A | $110.87M 14.75% | $54.27M -51.04% | Avg: $118.68M Low: $72.06M High: $205.82M avg. 118.65% | Avg: $166.16M Low: $100.89M High: $288.16M avg. 40.00% | Avg: $231.10M Low: $140.32M High: $400.78M avg. 39.08% | |
FAQ
What is KalVista Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 203.28% in 2026-2028.
We have gathered data from 4 analysts. Their low estimate is -46.57M, average is -25.81M and high is 29.00M.
What is KalVista Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 26.36% in 2026-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $71.84M, average is $118.32M and high is $205.19M.
What is KalVista Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 322.67% in 2026-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.67, average is -$0.5 and high is $1.04.
What is the best performing analyst?
In the last twelve months analysts have been covering KalVista Pharmaceuticals stock. The most successful analyst is Serge Belanger.